Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Malignant Solid Neoplasm: early-phase trial registry
46 of 93 indexed Metastatic Malignant Solid Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #145 of 28,707 conditions by registered trial count.
93 US clinical trials · 46 currently recruiting · #145 of 28,707 conditions by registered trial count
Metastatic Malignant Solid Neoplasm: 93 US clinical trials tracked, 46 recruiting.
Metastatic Malignant Solid Neoplasm is the subject of 93 registered US clinical trials on ClinicalTrials.gov, 46 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 76 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 38 of these trials.
Enrollment posture brief
Registry condition metastatic-malignant-solid-neoplasm
OPEN 46 | RECR 49% | LATE 2 | EARLY 76 | RANK #145 | SPON 38
Volume-matched condition peers
Nearest open-share peer: Anxiety Disorders (49% recruiting · 85 trials)
Metastatic Malignant Solid Neoplasm lists 46 open slots (49% of 93 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Malignant Solid Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Malignant Solid Neoplasm is recruiting above its size-band peers.
46 of 93 indexed trials (49.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Malignant Solid Neoplasm research.
National Cancer Institute (NCI) accounts for 38 of 93 trials (40.9%). 21 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Malignant Solid Neoplasm trials plan to enrol fewer than 100 people.
Median target enrolment is 58 among the 93 trials that report a genuine target (sentinel values excluded). 68 of those (73.1%) plan for fewer than 100 participants.
-
Metastatic Malignant Solid Neoplasm research is mostly interventional.
87 interventional and 6 observational studies make up this index (93.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
93 total, page 1 of 2
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
National Cancer Institute LAO
NCT02474160
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
NCT05564377
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Mayo Clinic
NCT06075524
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
NCT06311214
Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients
Mayo Clinic
NCT06015932
Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial
NRG Oncology
NCT06745024
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
NCT06500455
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
M.D. Anderson Cancer Center
NCT02710253
Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis
M.D. Anderson Cancer Center
NCT05059678
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
NCT03907475
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
M.D. Anderson Cancer Center
NCT04693468
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT05638295
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT06223542
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03184038
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Rahul Aggarwal
NCT03682289
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
NCT05327010
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
Tianhong Li
NCT05101356
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
Mayo Clinic
NCT05222620
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute (NCI)
NCT05687136
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Northwestern University
NCT06630416
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
National Cancer Institute (NCI)
NCT05691491
Imaging of Solid Tumors Using 18F-TRX
Rahul Aggarwal
NCT06942104
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
NCT04585958
TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
University of California, Davis
NCT07189195
Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal
Mayo Clinic
NCT05530759
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
NCT04771520
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
NCT04329494
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
National Cancer Institute (NCI)
NCT06364410
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
National Cancer Institute (NCI)
NCT05372640
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
National Cancer Institute (NCI)
NCT05687110
MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
Mayo Clinic
NCT06911008
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
NCT05039632
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
NCT04693377
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
National Cancer Institute (NCI)
NCT06606990
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Rutgers, The State University of New Jersey
NCT03428802
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
OHSU Knight Cancer Institute
NCT06320405
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
National Cancer Institute (NCI)
NCT07137416
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
National Cancer Institute (NCI)
NCT05691517
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
National Cancer Institute (NCI)
NCT05803382
Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases
City of Hope Medical Center
NCT06549478
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
Fred Hutchinson Cancer Center
NCT06043713
Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors
City of Hope Medical Center
NCT05733949
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Anusha Kalbasi
NCT04119024
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
M.D. Anderson Cancer Center
NCT04879121
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
City of Hope Medical Center
NCT05371132
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
Emory University
NCT06328686
NCI COVID-19 in Cancer Patients, NCCAPS Study
National Cancer Institute (NCI)
NCT04387656
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
SWOG Cancer Research Network
NCT05455606
Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses
SWOG Cancer Research Network
NCT04960787
A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer
Ohio State University Comprehensive Cancer Center
NCT05215769
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 54 |
| Phase 2 | 22 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Malignant Solid Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Malignant Solid Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Malignant Solid Neoplasm page
93 registered trials, 46 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 46 Metastatic Malignant Solid Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Metastatic Malignant Solid Neoplasm trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Malignant Solid Neoplasm condition card totals 93 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.